TIL News and Press, Instil Bio Inc. From 08/12/21

- Presented compassionate use study in advanced melanoma demonstrating 67% of subjects achieved an objective response with 19% achieving a complete response - Received orphan drug designation from the U.S. FDA for lead asset ITIL-168 - Developed 21-day manufacturing proces...

Baker Brothers’ 13F portfolio value decreased from $26.54B to $23.07B this quarter. The large stake in Alexion Pharmaceuticals was decreased during the quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~57% of the portfol...

Iovance Biotherapeutics (IOVA) drops 5.1% premarket after announcing clinical data for its tumor infiltrating lymphocyte ((TIL)) therapy LN-145 in patients with metastatic non-small cell lung cancer (mNSCLC). The overall response rate ((ORR)) was 21.4% (n=28, one complete response a...

DALLAS, June 01, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced that management wil...

Instil Bio (TIL): Q1 GAAP EPS of -$0.66 beats by $0.02.As of March 31, 2021, cash and cash equivalents totaled $609.6M.Press Release For further details see: Instil Bio EPS beats by $0.02

IPO in March 2021 raising $368M in gross proceeds Received orphan drug designation from the U.S. FDA for lead product candidate ITIL-168 DALLAS, May 13, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical com...

At the mid-April American Association of Cancer Research Annual Meeting, bleeding-edge oncology company Instil Bio (NASDAQ: TIL) reported promising results for one of its candidate therapies. In a compassionate-use program, the company's tumor-infiltrating lymphocyte (TIL) thera...

Instil Bio (TIL) has added ~7.0% in the pre-market after announcing that the FDA has granted the orphan drug designation for the treatment of melanoma stages IIB to IV with its ITIL-168 TIL therapy.The orphan drug title enables the drug’s developers to claim benefit...

DALLAS, April 27, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL) received orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for the treatment of melanoma stages IIB to IV with its ITIL-168 TIL therapy. “The Orphan D...

67% overall response rate and 19% complete response rate in 21 patients All complete responders remained in remission at time of data cut-off DALLAS, April 12, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceuti...